Popular terms

Autoimmune Diseases topics
Immune Diseases
Autoimmune Disease
Autoimmune Diseases
Immune Disease
Autoimmune
Rheumatoid Arthritis
Antibodies
Proliferative
Nucleotide
Antagonist
Infectious Diseases
Inflammatory Disease
Infectious Disease
Infectious
Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Diseases patents



      

This page is updated frequently with new Autoimmune Diseases-related patent applications.




Date/App# patent app List of recent Autoimmune Diseases-related patents
02/04/16
20160033528 
 Methods for selecting peptides that bind to disease specific antibodies, disease specific peptides and uses thereof patent thumbnailMethods for selecting peptides that bind to disease specific antibodies, disease specific peptides and uses thereof
Provided herein is a method for selecting and expanding polypeptide epitopes against disease-specific antibodies present in blood across a wide variety of antibody-mediated infectious and autoimmune diseases. In particular, high-throughput selection methods are provided for selecting and expanding disease-relevant polypeptide epitopes against disease-specific antibodies present in a sample from a subject using polypeptide epitope libraries.
The Regents Of The University Of California


02/04/16
20160031934 
 Dipeptide and tripeptide epoxy ketone protease inhibitors patent thumbnailDipeptide and tripeptide epoxy ketone protease inhibitors
Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of formula (x): and pharmaceutically acceptable salts and compositions including the same.
Onyx Therapeutics, Inc.


02/04/16
20160031891 
 Inhibitors of bruton's tyrosine kinase patent thumbnailInhibitors of bruton's tyrosine kinase
Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.

02/04/16
20160030439 
 Methods for the treatment of autoimmune diseases patent thumbnailMethods for the treatment of autoimmune diseases
The present invention provides a method for inducing cd8+foxp3+ regulatory t cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates t-cell receptor (tcr) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject.
Ucl Business Plc


01/28/16
20160024508 
 Method for identifying biologically active oligonucleotides capable of modulating the immune system patent thumbnailMethod for identifying biologically active oligonucleotides capable of modulating the immune system
The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer..
Index Pharmaceuticals Ab


01/28/16
20160024220 
 Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis patent thumbnailPharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-cd6 monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular


01/28/16
20160024219 
 Anti-cd52 antibodies patent thumbnailAnti-cd52 antibodies
Anti-human cd52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments.
Genzyme Corporation


01/28/16
20160024215 
 Llt-1 antibodies with new functional properties patent thumbnailLlt-1 antibodies with new functional properties
The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (llt1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which llt1- and cd161-expressing cells play a role in disease pathogenesis..
Centre National De La Recherche Scientifique


01/28/16
20160024183 
 Synthetic peptides for the treatment of autoimmune diseases patent thumbnailSynthetic peptides for the treatment of autoimmune diseases
The present invention provides synthetic peptides, including peptides comprising a plurality of epitopes, each epitope being derived from a different protein, and peptides comprising a plurality of citrullinated residues. The present invention also related to use of said peptides for the treatment of autoimmune diseases and disorder..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


01/28/16
20160022788 
 Compositions and methods for treating autoimmune diseases patent thumbnailCompositions and methods for treating autoimmune diseases
The present invention provides compositions comprising immunologically effective amounts of one or more autoimmune disease associated antigens or antigenic fragments or derivatives thereof and one or more th2 promoting adjuvants. The compositions may optionally comprise one or more th2 promoting tlr2 ligands.
Albany Medical College


01/28/16
20160022767 

Protein particles comprising disulfide crosslinkers and uses


This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds.
Emory University


01/28/16
20160022759 

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan-sulfate mediated macropinocytosis


Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences


01/21/16
20160017024 

Fam150a, fam150b, and fam150 antagonists and uses thereof


Methods of identifying and using fam150a agents, fam150b agents, and fam150 antagonists are provided. Methods of identifying and using ltk agonists (including ltk agonist antibodies, fam150a agents, and fam150b agents) and fam150 antagonists are provided.
Five Prime Therapeutics, Inc.


01/21/16
20160016946 

Methods, compounds, and compositions for the treatment of angiotensin-related diseases


Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.. .
University Of Southern California


01/21/16
20160016904 

Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof


The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (i) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
Arena Pharmaceuticals, Inc.


01/21/16
20160015751 

Method for enhancing a function of a t cell


Disclosed is a method for enhancing the function of a t cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (pd-l1) and/or programmed death-1 ligand 2 (pd-l2) in the t cell. Also disclosed is a function-enhanced t cell which is produced by the function enhancement method.
Takara Bio Inc.


01/21/16
20160015729 

Glycan-based drugs, therapies and biomarkers


The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed..

01/14/16
20160008608 

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism


An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

01/14/16
20160008440 

Use of cd83 in combination therapies


The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of cd83. In some embodiments, cd83 is coadministered to a subject with at least one other immunosuppressive compound.
Argos Therapeutics, Inc.


01/14/16
20160008397 

Immunomodulation by controlling expression levels of micrornas in dendritic cells


Compositions and methods of modulating an immune response by controlling expression levels of micrornas in dendritic cells are disclosed. In particular, the invention relates to modified dendritic cells and methods of using such dendritic cells in cellular therapy for treating various immune conditions and diseases, including transplant rejection, inflammatory disorders, autoimmune diseases, allergies, infectious diseases, immunodeficiency, and cancer..
The Board Of Trustees Of The Leland Stanford Junior University


01/07/16
20160002241 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Llc.


01/07/16
20160002225 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that inhibit bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.

01/07/16
20160002187 

Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


01/07/16
20160000877 

Compositions and methods for modulating gamma-c-cytokine activity


The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc


01/07/16
20160000867 

Compositions and methods for modulating the immune system


A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
Bioincept, Llc


01/07/16
20160000835 

Human uterine cervical stem cell population and uses thereof


The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or conditioned medium for treating or preventing cancer, precancerous lesions, inflammatory diseases, autoimmune diseases, chronic pathologies or infectious diseases, diseases associated to tissue loss, or for use in diagnostic, prognostic or treatment of fertility disorders, as well as for cosmetic treatment..
Fundacion Para La Investigacion Con Celulas Madre Uterinas


12/31/15
20150377879 

Peptoids that bind specific antigens


Combinatorial libraries were generated providing a vast number of diverse peptoid ligands. From these libraries, ligands were identified which specifically bind molecules associated with autoimmune diseases, such as antibodies specific to aquaporin-4 (aqp4), binding of which to aqp4 causes the autoimmune disease, neuoromyelitis optica.
The Scripps Research Institute


12/31/15
20150376294 

Anti-pad2 antibodies and treatment of autoimmune diseases


The present invention relates to anti-peptidylarginine deiminase 2 (pad2) antibodies and anti-pad2 antibodies for use in the treatment of autoimmune diseases characterized by extracellular citrullination, such as rheumatoid arthritis (ra). The invention further relates to a method for treatment of an autoimmune disease characterized by extracellular citrullination comprising the administration of a suitable amount of an anti-pad2 antibody to a subject..
Rigshospitalet


12/31/15
20150376285 

Antibody molecule for human gm-csf receptor alpha


Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (gm-csfrα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g.
Zenyth Operations Pty. Ltd.


12/31/15
20150376174 

Azole benzene derivative


The present invention provides: a compound represented by formula (i) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.. .
Teijin Pharma Limited


12/31/15
20150376173 

Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent


The present invention relates to novel compounds of formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical composition comprising the same as an active component. The compounds according to the present invention are effective on extensive autoimmune diseases and chronic inflammatory diseases including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulation disorders..
Lg Life Sciences Ltd.


12/31/15
20150374855 

Oral contrast medium for the diagnostic investigation of the gastrointestinal tract by means of mpi


The invention relates to a pharmaceutically acceptable colloidal suspension, which comprises a microcapsule, which is enclosed by a container (“double container”), wherein the microcapsules comprise magnetic particles in a colloidal solution. The invention further relates to the use of said pharmaceutically acceptable colloidal suspension as an oral contrast medium for the diagnostic investigation of the gastrointestinal tract and the use of the contrast medium to diagnose proliferative diseases, inflammatory and autoimmune diseases, infectious diseases and hormonal and hereditary diseases in the gastrointestinal tract..
Topass Gmbh


12/24/15
20150368611 

Induced regulatory t cell and use thereof


The present invention relates to a transduced t cell precursor prepared by introducing a gene construct comprising a polynucleotide encoding c/ebp (ccaat/enhancer binding protein) to a t cell precursor and overexpressing the c/ebp thereby, wherein the transduced t cell precursor is capable of differentiating into a regulatory t cell and an induced regulatory t cell differentiated therefrom. The transduced t cell precursor and the induced regulatory t cell may be useful for preventing and treating autoimmune diseases, inflammatory diseases and graft rejections caused by the malfunction of immune response..
Seoul National University R&db Foundation


12/24/15
20150368261 

Conjugates and small molecules which interact with the cd16a receptor


The invention is related to medicine, in particular, to oncology and immunology. The novel compounds of the general formula 1 or 2, exhibiting affinity for cd16a receptor have been proposed.
Alla Chem, Llc


12/17/15
20150361039 

Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor


The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited


12/10/15
20150353514 

Amphiphilic derivatives of triazamacrocyclic compounds, products and compositions including same, and synthesis methods and uses thereof


The invention relates to amphiphilic derivatives of a triazamacrocyclic compound, as well as to said derivatives as active molecule transporters. The invention also relates to a nanodrug including at least one amphiphilic derivative of a triazamacrocyclic compound and at least one active molecule of a protein such as an antibody, in particular for the treatment of autoimmune diseases or for the treatment of cancer..
Biocellchallenge


12/10/15
20150352219 

Conjugate compounds


The invention relates to sphingoglycolipid analogues and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.. .
Callaghan Innovation Research Limited


12/10/15
20150352109 

Kinase inhibitor and treatment of related diseases


Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases..
Beijing Reciprocapharmaceuticals Co. Ltd.


11/26/15
20150337041 

Methods and compositions for treating autoimmune diseases or conditions


The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to nkg2d receptors present on the surface of cells underlying the disorders..
Fred Hutchinson Cancer Research Center


11/19/15
20150330968 

Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions


The present invention relates to methods and assays for identifying agents capable of modulating gpr84 activity in cells, in particular agents that inhibit gpr84-agonist stimulated chemotaxis. Inhibition of gpr84-agonist stimulated chemotaxis is useful in the prevention and/or treatment of inflammatory conditions.
Galapagos Nv


11/19/15
20150329864 

Design of oligonucleotide analogs as therapeutic agents


It is believed that the compounds and compositions as described herein have therapeutic utility against a variety of diseases, including viral diseases, autoimmune diseases (such as, allergy, asthma, and inflammatory disorders) and cancer.. .

11/19/15
20150329637 

Depletion of il23r expressing cells in the treatment of various diseases


The present invention relates, for example, to depletion of il23r expressing cells in the treatment of disease and, in an embodiment thereof, to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to il23r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in, for example, treating inflammatory and/or autoimmune diseases and/or cancer.. .
Numab Ag


11/19/15
20150329541 

Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
The Walter And Eliza Hall Institute Of Medical Research


11/05/15
20150315196 

Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases


Or a pharmaceutically acceptable salt or solvate thereof.. .

11/05/15
20150315191 

4-position substituted pyrazolopyrimidine derivative, and use thereof in drug preparation


The invention provides a new pyrazolopyrimidine derivative and a simple, efficient and low-cost preparation method thereof. The pyrazolopyrimidine derivative of the invention has good inhibitory activity for multiple kinases, has inhibitory action on multiple solid tumors, leukemia and autoimmune diseases, provides a new effective choice for preparation of kinase inhibitors, medicines for autoimmune diseases, angiogenesis inhibitors and antitumor drugs, and has good application prospect..

11/05/15
20150315189 

18f-labelled folates


The present invention is directed towards a new method of synthesis of 18f-folate radiopharmaceuticals, wherein fluorine-18 is attached to a pteroate (or folate) or derivative thereof, through direct radiolabeling with 18[f]fluoride, as well as 18f-folate radiopharmaceuticals obtained by such method of synthesis and their use in diagnosis and monitoring of cancer therapy and therapy of inflammatory and autoimmune diseases.. .
Merck & Cie


11/05/15
20150315128 

Bicyclic compounds


And/or a salt thereof; wherein r is —oh or —op(o)(oh)2. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

11/05/15
20150313899 

Compounds and treating autoimmune diseases


Wherein x and y independently are o or nr1; each r1 is independently h or c1-c6 alkyl; ring a is aryl; each r2 independently is h, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two r2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; r3 and r4 independently are h or c1-c6 alkyl; and r5 is halo, cyano, or c1-c6 alkyl.. .

10/29/15
20150307520 

Novel heteroaryl and heterocycle compounds, compositions and methods thereof


Disclosed are novel heteroaryl and heterocycle compounds of formula i-1, i-2 or i-3 and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of pi3k and for treating inflammatory and autoimmune diseases and cancer.. .
Hutchison Medipharma Limited


10/29/15
20150306103 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.


10/22/15
20150301042 

Methods of using chimeric receptors to identify autoimmune disease


The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of graves' disease.
Diagnotic Hybrids, Inc.


10/22/15
20150299197 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed herein are compounds that inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.. .
Abbvie Inc.


10/22/15
20150299185 

Novel imidazopyridine derivatives as a tyrosine kinase inhibitor


Provided is a novel imidazopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.. .
Hanmi Pharm. Co., Ltd.


10/22/15
20150299103 

Prodrugs of monomethyl fumarate (mmf)


The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (mmf) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis..
Ratiopharm Gmbh


10/22/15
20150297640 

Method of controlling administration of cancer antigen


The present invention is directed to mammalian bi-specific t cells and methods for using these bi-specific t cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific t cells that express a viral antigen t cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting t-cells which express viral antigen.
City Of Hope


10/15/15
20150291554 

Bruton's tyrosine kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Methods for the preparation of the compounds are disclosed.

10/15/15
20150291509 

Novel biphenyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising the same as active ingredient


The present invention relates to a novel biphenyl derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising the same as an active ingredient, and methods for treating inflammatory disease or autoimmune diseases with the pharmaceutical composition. Novel biphenyl derivatives according to the present invention promote the phagocytosis of macrophages and inhibit the chemotaxis to exhibit excellent inflammation terminating and anti-inflammatory effects and thus can be effectively used as therapeutic agents for inflammatory diseases or autoimmune diseases..

10/15/15
20150290317 

Combination of anti-cd20 antibody and pi3 kinase selective inhibitor


Highly effective combinations of a compound of formula a (a pi3kδ selective inhibitor) and anti-cd20 antibodies are provided herein for the treatment and amelioration of pi3kδ and/or cd20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases.

10/15/15
20150290284 

Ideotypically modulated pharmacoeffectors for selective cell treatment


In a method embodiment, a method includes introducing a plurality of ideotypically modulated pharmacoeffectors (imp) into a population of cells. Each imp may include a detection domain and an activation domain.

10/08/15
20150284467 

Antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases


The invention relates to antibodies or antibody fragments that bind cd269 (bcma), thereby disrupting the interaction between cd269 and its native ligands (baff and april), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.. .

10/08/15
20150284459 

Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways


Described herein are novel compositions comprising il-27 or nfil-3 modulators (i.e., inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating tim-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases..

10/08/15
20150284410 

Rna polymerase i inhibitors and uses thereof


Provided are novel compounds which are capable of inhibiting an activity of rna polymerase i, and uses thereof in treating diseases or disorders modulated by rna polymerase i, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.. .

10/08/15
20150284399 

Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof


The present invention relates to salts, processes, and process intermediates useful in the preparation of (r)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-1-yl)acetic acid of formula (ia), salts, and crystalline forms thereof. The compound (r)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-1-yl)acetic acid has been identified as an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis)..

10/08/15
20150283127 

Saquinavir-no for immunomodulation


The nitric ester of saquinavir, or its non-toxic salts, solvates or crystalline/polymorphic forms, i useful in the treatment of autoimmune diseases, particularly in disease mediated by pro-inflammatory cytokines. Examples of diseases which may be treated include idiopathic addison's disease, autoimmune hepatitis, biliary cirrhosis, primary sclerosing cholangitis, guillain barré syndrome, hashimoto's thyroiditis, psoriasis, rheumatoid arthritis, sjogren's syndrome, systemic lupus erythematous, type 1 diabetes mellitus and uveitis of ischemia-reperfusion, graft versus host diseases, graft rejection, endo and exo-toxemia and gouty arthritis..

10/01/15
20150275175 

Therapeutic apoptotic cell preparations, producing same and uses thereof


The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (gvhd) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis..
Enlivex Therapeutics Ltd.


10/01/15
20150274828 

Human anti-human epidemic growth factor receptor antibody and encoding gene and application thereof


The present invention provides human anti-human epidermal growth factor receptor (egfr) antibodies and their encoding genes and applications thereof. By gene engineering means and phage surface display technology, the present invention screens anti-human egfr gene engineering single chain antibody from fully synthetic single chain human antibody library, and obtains the antibody variable gene sequence thereof, and based thereon, constructs intact human monoclonal antibody, to further obtain high-purity antibody protein.
Shanghai Serum Biotechnology Co., Ltd.


10/01/15
20150274806 

Fibronectin based scaffold domain proteins that bind il-23


The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (il-23), specifically the p19 subunit of il-23. The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases.
Bristol-myers Squibb Company


10/01/15
20150274726 

Substituted tricyclic benzimidazoles as kinase inhibitors


Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (i) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit cdk8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases.
Selvita Sa


10/01/15
20150274722 

Novel compound useful for the treatment of degenerative and inflammatory diseases


A novel compound able to inhibit jak is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6.. .
Galapagos Nv


10/01/15
20150272997 

Mesenchymal stem cells and uses therefor


Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
Mesoblast International Sárl


09/24/15
20150266882 

Pyrazolo[4,3-d]pyrimidines as kinase inhibitors


The present invention relates to novel compounds of formula (i) that are capable of inhibiting one or more kinases, especially syk (spleen tyrosine kinase), lrrk2 (leucine-rich repeat kinase 2) and/or mylk (myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases.
Origenis Gmbh


09/24/15
20150266824 

Pyrazole amide derivative


The present invention relates to a novel compound having a function of inhibiting rorγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases..
Teijin Pharma Limited


09/24/15
20150265701 

Immunomodulating compositions and uses therefor


The present invention discloses immunomodulating compositions. More particularly, the present invention discloses compositions comprising an immune-modulating agent and a lectin-interactive agent, which are useful for stimulating and prolonging host immune cell responses.

09/17/15
20150259397 

Long acting trial receptor agonists for treatment of autoimmune diseases


Methods of treating an autoimmune disease such as rheumatoid arthritis, methods of increasing apoptosis of pro-inflammatory immune cells or synoviocytes, methods of increasing the quantity of the anti-inflammatory regulatory t cells, and methods of slowing the progression of inflammation in a subject include systemically administering to the subject a pharmaceutical composition including an effective amount of a trail-conjugate. Preferably, the trail-conjugate is effective for at least 3 days, more preferably at least 7 days, without being part of a nanocomplex that modulates the circulation half-life or release kinetics of the trail-conjugate.
Theraly Pharmaceuticals Inc.


09/17/15
20150259340 

Novel kinase inhibitors


The present invention relates to novel compounds of formula (i) that are capable of inhibiting one or more kinases, especially syk (spleen tyrosine kinase), lrrk2 (leucine-rich repeat kinase 2) and/or mylk (myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases.
Origenis Gmbh


09/17/15
20150259310 

Acylpiperazines as inhibitors of transglutaminase and their use in medicine


The present invention relates to novel compounds of formula i capable of inhibiting tissue transglutaminase, and uses of the same in medicine. In particular, the invention provides compounds for use in the treatment of prevention of disease and conditions such as fibrosis (e.g.
Aston University


09/17/15
20150258094 

Nanocarriers and their processing for diagnostics and therapeutics


The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis..
Rhode Island Hospital


09/10/15
20150252110 

Anti-cd19 antibodies


The present invention provides humanized, chimeric and human anti-cd19 antibodies, anti-cd19 antibody fusion proteins, and fragments thereof that bind to a human b cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various b-cell disorders, including b-cell malignancies and autoimmune diseases.
Immunomedics, Inc.


09/10/15
20150250862 

Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis


Nanoparticles to treat autoimmune diseases and hiv infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (mhc) class i antigen e (hla-e) linked to a peptide, and wherein the hla-e-peptide complex is linked to the surface of the nanoparticle.
Dana-farber Cancer Institute, Inc.


09/03/15
20150247850 

Gp2 isoforms and their use in autoantibody capture


The invention relates to a method for binding or capturing autoantibodies directed to various glycoprotein 2 (gp2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of gp2.
Ga Generic Assays Gmbh


09/03/15
20150246953 

Immunoglobuljin-binding human mycoplasma antigens and methods of use thereof


Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (mgus), which methods include administering an agent effective to treat a mycoplasma infection. The invention also relates to a new class of antigen, mg281 protein {also referenced as protein m), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins.
The Scripps Research Institute


09/03/15
20150246914 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


09/03/15
20150246913 

Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of formula (i) or (ii), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject.
Beth Israel Deaconess Medical Center, Inc.


08/27/15
20150241448 

Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders


The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component c-like (lancl) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs.
Virginia Tech Intellectual Properties, Inc.


08/27/15
20150239957 

Ig-pconsensus gene vaccination protects from antibody-dependent immune pathology in autoimmune disease


The disclosure provides a fusion polypeptide and compositions useful for treating autoimmune diseases and disorders. The fusion polypeptide comprises a first domain comprising a self antigen which is a conserved sequence found in t cell determinants in the fr1/cdr1 region of vh of human and murine igg antibodies, particularly seq id no:2 or an antigenic fragment thereof; and a second domain comprising a heterologous polypeptide or small molecule..
Università Degli Studi Di Genova


08/27/15
20150239897 

Pyrrolopyrimidine compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.


08/27/15
20150238548 

Lactobacillus strain, composition and use thereof for treating syndromes and related complications of autoimmune diseases


The present invention is related to a lactobacillus strain, composition and use thereof for treating autoimmune disease and related complications. The composition comprises at least one isolate of lactobacillus paracasei strain gmnl-32, l.
Genmont Biotech Incorporation


08/27/15
20150238493 

Medicament for treating peripheral neuropathies


The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (hsv), and then administering to the human the compound anti-hsv agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (neurodermatitis, prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, parkinson's disease, anemia, cytopenia those among the diagnostic criteria..

08/27/15
20150238445 

Composition using metformin for preventing or treating immune diseases including lupus


The present invention relates to a composition for preventing or treating immune diseases through the suppression of b cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of b cell activity which is a cause of disease.
Catholic University Industry Academic Cooperation Foundation


08/20/15
20150231281 

Inflammation imaging and therapy


An imaging agent comprising a conjugate of an oligosaccharide moiety with an imaging moiety. The oligosaccharide is lewis a or lewis b or a mimetic thereof, or a pharmaceutically acceptable salt or pegylated form of lewis a or lewis b or its mimetics.
Isis Innovation Limited


08/13/15
20150225398 

Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

08/13/15
20150224199 

Pharmaceutical compositions for the treatment of inflammatory disorders


Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

08/13/15
20150224146 

Cell populations having immunoregulatory activity, isolation and uses


The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.. .
Consejo Superior De Investigaciones Cientificas


08/13/15
20150224141 

Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases


Methods for enhancing the suppressive function of myeloid derived suppressor cells (mdscs) for the treatment of autoimmune diseases using small compounds are disclosed. In certain aspects, the small compounds are glatiramer acetate and mitogen activated protein (map) kinase inhibitors.
Icahn School Of Medicine At Mount Sinai


08/06/15
20150218260 

Interleukin-2 fusion proteins and uses thereof


The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (il-2). More particularly, the invention concerns fusion proteins of immunoglobulins and mutant il-2 that exhibit improved properties for use as therapeutic agents, e.g.
Hoffman-la Roche Inc.


08/06/15
20150218239 

Fcrn antagonists and methods of use


Provided are novel fcrn antagonist compositions comprising a variant fc region that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region. Also provided are fcrn antagonists with enhanced cd16 binding affinity.
The Board Of Regents Of The University Of Texas System


08/06/15
20150216971 

Methods for treating gi syndrome and graft versus host disease


It has been discovered that administering therapeutically effective amounts of an antibiotic that kills gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic t lymphocyte (ctl)-induced killing and/or by damage to endothelial microvasculature, including radiation gi syndrome, cgvhd disease, inflammatory diseases and autoimmune diseases.. .
Sloan Kettering Institute For Cancer Research




Autoimmune Diseases topics: Immune Diseases, Autoimmune Disease, Autoimmune Diseases, Immune Disease, Autoimmune, Rheumatoid Arthritis, Antibodies, Proliferative, Nucleotide, Antagonist, Infectious Diseases, Inflammatory Disease, Infectious Disease, Infectious, Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.5248

5554

0 - 1 - 101